UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): February 12, 2010
ACCESS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
0-9314
|
83-0221517
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
|
|
2600
Stemmons Freeway, Suite 176
Dallas,
TX 75207
(Address
of principal executive offices) (Zip Code)
(214)
905-5100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction
A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS, COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS
|
- -------------------------------------------------------------
Effective February 12, 2010, David P.
Luci resigned from the board of directors of Access Pharmaceuticals,
Inc.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Access
Pharmaceuticals, Inc.
(Registrant)
By:
/s/ Stephen B. Thompson
------------------------------
Stephen B.
Thompson
Vice President
and
Chief
Financial Officer
Dated February
18, 2010
2